Kornimate/medical-research-clean huggingface dataset:
criteria analysis for ventilatory support adjustment of mechanical ventilation

Conditions: Acute Mechanical Ventilatory Failure

Summary: the indications for mechanical ventilation (mv) include excessive work of breathing, with or without evidence of respiratory muscle fatigue. the setting of the mv is still a challenge because it is based on criteria understudied, often subjective and observer-dependent. despite several studies, to our knowledge has never been done before is the precise definition of the optimal range of ventilatory support. novel and recognizable diagnostic techniques will be applied. no single parameter of the breathing pattern has good accuracy for the adjustment of ventilatory support. non-invasive measures such as p0.1 and rate of muscle relaxation may have good accuracy for the adjustment of ventilatory support.

use of excessive pressure support

Eligibility criteria:
inclusion criteria: * patients under invasive mechanical ventilation for 48h * patients without the objective of complete rest of the respiratory muscles. this decision will be on the discretion of the attending physician, * spontaneous breathing, * clinically stability. exclusion criteria: * previous disease of the central nervous system that can lead to respiratory changes. * previous disease of the peripheral nervous system that can lead to respiratory changes * previous muscular disease.
sublingual versus endovenous fentanyl for pain treatment in trauma patients in the emergency room

Conditions: Acute Pain Due to Trauma

Summary: the purpose of this study is to determine the non-inferiority of the efficacy of sublingual given fentanyl versus endovenous given fentanyl for patients in the emergency departement.

fentanyl endovenous (ev) is an excellent analgesic drug for pain relief in acute traumatic pain. fentanyl sublingual (abstral ®) is an excellent analgesic drug in the breakthrough pain relief in oncologic patients. the immediate (10 minutes) effect and the ease of administration of sublingual fentanyl could be a possibility for a fast pain relief in remote areas such as mountain rescue missions. patients will be recruited according to a randomized list to fentanyl ev or fentanyl sublingual versus placebo oral or placebo ev. safety issues like control of vital signs will be warranted

Eligibility criteria:
inclusion criteria: * trauma on the limbs with a pain score of 4 or more * asa i - ii exclusion criteria: * children \< 18 years * cognitive impairment: brain injury, intoxication, analgesia * weight under 50 kg and more then 100 kg * other injuries like chest trauma with respiratory insufficiency, suspect liver or spleen injury, amputation; * chronic analgesic use or misuse * allergy * fear of needles * pregnancy * speech difficulties

Keywords: fentanyl transmucosal administration endovenous administration pain therapy
the effects of compression stockings on pressure parameters in patients with chronic venous insufficiency

Conditions: Venous Insufficiency

Summary: the main objective of this study is to obtain data to determine, in each individual with and without wearing compression stockings of different strengths and during different postures, the relationship between interface pressure and the area and circumference of the great saphenous vein and posterior tibial veins in the calf and ankle.


Eligibility criteria:
inclusion criteria: * the participant must have given his/her informed and signed consent * the participant must be insured or beneficiary of a health insurance plan inclusion criteria for patients in the venous insufficiency group: * ceap (clinical-etiology-anatomy-pathophysiology) classification : c1s, c3 or c5 inclusion criteria for healthy volunteers * general good health * subgroups including: * sedentary volunteers (\< 2hours of physical activity per week) * active volunteers (between 2 and 6 hours of physical activity per week) * athletic volunteers (over 6 hours of physical activity per week for at least 1 year) exclusion criteria: * the participant is participating in another study, except the "volumetric" counterpart to the present study * the participant is in an exclusion period determined by a previous study * the participant is under judicial protection, under tutorship or curatorship * the participant refuses to sign the consent * it is impossible to correctly inform the participant * the participant is pregnant, parturient, or breastfeeding * arterial vascular disease, heart, lymph, renal, hepatic, oncologic, metabolic or endocrine or any other condition that may cause or exaggerate edema exclusion criteria for healthy volunteers: * risk for abnormal bleeding (hemophilia, anticoagulation or antiplatelet) * taking diuretics or corticoids

Keywords: compression stockings physiopathology
eye-tracking investigation of clinical measures in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in ms patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. the training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of ms disease severity and cognitive status.

this study will use a single group design in a cohort of ms patients. eligible patients with ms will be selected and categorized based on their expanded disability status scale (edss) score. patients eye movements will be captured using the patented eye-tracking technology at one single time point. in addition to the eye-tracking tests, patient phenotypes will be further detailed via brief functional and cognitive assessments using the edss, brief international cognitive assessment for ms (bicams) and multiple sclerosis functional composite (msfc). all patients will be required to participate in a single session.

Eligibility criteria:
inclusion criteria: * able to provide informed consent * aged 18 years or older at the time of enrollment * able to read in either french or english * able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses * confirmed diagnosis of ms as per the macdonald criteria, irrespective of ms subtype (relapsing-remitting (rrms), secondary-progressive (spms), primary-progressive (ppms), and progressive-relapsing (prms)) * neurologist-determined edss score between 1.0-8.0 exclusion criteria: * evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control * presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia) * diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments * having started a new prescription medication or having changed the dose of a medication known to influence ocular motor visual function (e.g. benzodiazepines, antipsychotics and anticonvulsants) within the past three months * participants with non-disease related physical impairments to a leg, hand, or arm (e.g., broken bone or severe sprain) that would not allow completion of the assessments
ash research collaborative data hub

Conditions: Sickle Cell Disease; Multiple Myeloma

Summary: benign and malignant hematologic diseases are relatively rare conditions within the spectrum of medical practice in any one site of care. nonetheless, recent research in hematologic conditions from basic, translational, clinical and population perspectives offer the possibility of improving the way that these diseases are treated, and the outcomes experienced by patients. a repository that aggregates and validates this data across institutions and other practice settings is needed in order to identify variation in care, new findings, and further research.

the ash research collaborative (ash rc) is a non-profit organization established by the american society of hematology (ash) in 2018 that aims to improve the lives of those affected by blood diseases by fostering collaborative partnerships to accelerate progress in hematology. the foundation of the ash rc is its data hub, a technology platform that facilitates the exchange of information by aggregating in one place, and making available for inquiry, research-grade data on hematologic diseases. in 2019, ash rc launched its first research initiative, the sickle cell disease (scd) clinical trials network (ctn), with the goal of optimizing scd clinical research operations. as part of its core functions, the scd-ctn leverages the data hub to collect key information and identify gaps that will help advance scd research and treatment. the primary goal of the data hub is to further the scientific knowledge base for the diagnosis, understanding, and management of benign and malignant hematologic conditions by assembling data collected in routine clinical care and closed clinical trials. secondary goals are to characterize and study practice patterns for benign and malignant hematologic conditions in clinical practice, and to aggregate patient-reported data to further understand and improve the patient experience. these objectives will be fulfilled by amassing data from patients' electronic medical records and other data sources within institutions and networks to support prospective data collection efforts, such as those that include patient reported outcomes.

Eligibility criteria:
to be included in the data hub, patients must have documented sickle cell disease and/or active multiple myeloma since 2015.

Keywords: scd sickle cell myeloma
immunisation history survey - a study to measure levels of immunity to routine immunisations

Conditions: Immunization; Infection

Summary: to collect the immunisation history of participants enrolled in a previous vaccine study (rec 09/h0604/107) in order to assess the influence of genetic variation on the level of immunity to routine immunisations.

children aged 6 month to 13 years were enrolled in a study to compare the immunogenicity and safety of adjuvanted or non-adjuvanted influenza vaccines during the 2009 pandemic influenza season. nine-hundred and forty-nine children were recruited from 5 uk centres: oxford, southampton, bristol, exeter, and london in the previous study, dna was collected when individuals provided appropriate consent, to explore the genetic determinants of responses to vaccination. although, study participants consented for their medical records to be reviewed by members of the study team, and for these data as well as anonymised serum samples to be used in future research, routine immunisation histories were not collected before this study closed. in this study we wish to collect the full vaccination history of participants, as this information will be extremely important in interpreting results. we propose sending a letter to parents/guardians informing them of the study and asking whether they are willing for members of the study team to approach their general practitioner or the child health computer system in order to retrieve these records. immunisation histories will then be included with other non-identifiable information needed for analysis, and samples unlinked from personal identifiers prior to analysis.

Eligibility criteria:
inclusion criteria: * the inclusion criteria are consent in the original vaccine study (09/h0604/107) with explicit consent for samples to be stored and used in future research as well as consent to this subsequent study exclusion criteria: * individuals who do not have explicit consent for samples taken in the original vaccine study (09/h0604/107) to be stored for future research. * individuals who have not been consented into this study
study to evaluate the safety of repatha® in pregnancy

Conditions: Hypercholesterolaemia; Pregnancy

Summary: to evaluate pregnancy and infant outcomes among females diagnosed with familial hypercholesterolaemia (fh), exposed to repatha® during pregnancy. this includes follow-up of their infants to the age of 12 months

women diagnosed with familial hypercholesterolaemia (fh), treated at centres in europe, south africa and australia, with pregnancy confirmed during the study observation period and who provide informed consent to participate in the study. exposed subjects are women who received repatha® during pregnancy and/or breastfeeding; unexposed subjects are women who have not received repatha® during pregnancy and/or breast-feeding. in infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of repatha® dosing in the mother

Eligibility criteria:
inclusion criteria: * females diagnosed with familial hypercholesterolaemia (fh). * confirmed pregnancy during the study observation period. * pregnancies identified retrospectively but within the study period will be included * multiple pregnancies, occurring in the same woman within the study period, will all be included (as separate pregnancies) * provided informed consent to follow-up in this study, for subject and their infant(s) born during the study observation period exclusion criteria: there are no exclusion criteria

Keywords: hypercholesterolaemia lipid lowering therapies pregnancy
reproductibility of lumbar spine adc based on different post-processing softwares

Conditions: Low Back Pain

Summary: lumbar spine bone marrow is well explored in magnetic resonance imaging (mri) but some bone marrow diseases are hard to analyze with this method. furthermore, there is heterogeneity in normal bone marrow, called apparent diffusion coefficient (adc). histological and technical factors appear to be the cause, but the possible influence of the employed post-processing software has never yet been evaluated. the purpose of this study is to determine if there is variability in lumbar bone adc related to the post-processing software.

lumbar spine bone marrow is well explored in mri. some bone marrow diseases are hard to analyze in conventional mri, and diffusion-weighted imaging (dwi) could be an additional diagnostic feature. however, according to the literature, there is heterogeneity in normal bone marrow of the quantitative parameter that it provides, called apparent diffusion coefficient (adc). histological and technical factors appear to be the cause, but the possible influence of the employed post-processing software has never yet been evaluated. the purpose of this study is to determine if there is variability in lumbar bone adc related to the post-processing software.

Eligibility criteria:
inclusion criteria: * consecutive patients undergoing lumbar spine mri at university hospital of saint-etienne exclusion criteria: * \<18 years old

Keywords: low back pain mri
perindopril and telmisartan for the treatment of nonalcoholic fatty liver disease

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)

Summary: the aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with nafld and make comparison between the therapeutic effects of these two kind of drugs. this study is a randomized parallel control clinical trial which would be carried out in nanfang hospital, southern medical university. about one hundred and eighty patients would be randomly assigned to perindopril,telmisartan and amlodipine three groups.

inclusion criteria: 18-70 years old patients who were diagnosed with mild-moderate hypertension and nafld; the patients did not take aceis or arbs drugs six weeks before the inclusion; patients agreed to participate in the trial and signed the informed consent. exclusion criteria: there are no coexisting causes for chronic liver disease, such as viral, alcoholic,drug-induced and autoimmune liver diseases; patients with diabetes mellitus; patients with serious primary diseases; patients with mental disorder or can not take the medicine regularly; pregnancy and nursing mothers; allergic constitution or intolerance to aceis or arbs drugs. outcome measures include cap value of fibroscan,angiotensin ii,il-18，il-1β,aminotransferase,lipids and homa-ir.

Eligibility criteria:
inclusion criteria: * 18-70 years old patients who were diagnosed with mild-moderate hypertension and nafld; * the patients did not take aceis or arbs drugs six weeks before the inclusion; patients agreed to participate in the trial and signed the informed consent. exclusion criteria: * there are no coexisting causes for chronic liver disease, such as viral, alcoholic,drug-induced and autoimmune liver diseases; * patients with diabetes mellitus; patients with serious primary diseases; patients with mental disorder or can not take the medicine regularly; * pregnancy and nursing mothers; * allergic constitution or intolerance to aceis or arbs drugs.

Keywords: perindopril,telmisartan, efficacy, nafld
topical silver nanoparticles for microbial activity

Conditions: Foot Infection Fungal; Infection, Bacterial

Summary: silver nanoparticles are one of most nanoparticles use nowadays in the research area because it has specific physical and chemical properties, in medical fields silver nanoparticles can involve in diagnostic and treatment processes. silver nanoparticles have antibacterial, antiviral, antifungal, antiangiogenic, antioxidant, cosmetics, antitumor, anti-inflammatory, the drug carrier, imaging, water treatment, and biosensing effects. silver nanoparticles prepared with reducing agent tri-sodium citrate then incorporated in a topical cream to obtain a significant inhibition of the bacterial strains, inhibition of growth of bacterial strains in the face or other parts in the bodies.

1. preparation of vanishing cream vanishing cream is an emulsion base which is oil in water, the oil phase gives the cream shine and pearl look because of stearic acid in the oil. to form an emulsion, the alkali will react with stearic acid to form stearate soap. then mix sodium hydroxide (naoh) with potassium hydroxide (koh) to give cream hard and soft properties. 2. preparation of cream containing silver nanoparticles silver nanoparticles will be produced by using the reduction reaction method. the reaction involves heating silver nitrate at a high temperature with adding a reducing agent, the particles will produce as silver nanoparticles in liquid form. 3. characterization of the vanishing cream containing drug: 3.1. drug content: the amount of drug in cream will be determined by taking 100 mg of the cream formulation and dissolve it in 10 ml of methanol after that it will be filtrated. in addition, it will be analyzed the content of drug spectrophotometrically using (uv-vis) at specific λmax. 3.2. irritation to skin: in this test, the cream formulation will be applied to four healthy volunteers which they should not have any sensitivity to the drug. they will inform about the nature of the formulation and obtain a written approval from them about the irritation effect of the formulated cream. 4. anti-microbial studies: the antifungal action for formula will be studied using different 6 groups volunteers the inhibition microbial activity for all formulae were compared with known standard antimicrobial drugs.

Eligibility criteria:
inclusion criteria: * it is important to follow up and collect data, preferably for six months for the local and systemic activity of silver nanoparticles, to establish whether the infection recurrent or not. exclusion criteria: * larger numbers of participants having a different kind of skin infection are needed to test efficiency drug in order to produce more reliable data.
a genetic substudy associated with the avastin (bevacizumab) study mo19390 in patients with advanced or recurrent non-squamous cell lung cancer.

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this single arm genetic substudy of mo19390 will test the hypothesis that there is a positive relationship between mrna brcai levels and the response to different chemotherapy combinations plus avastin. a subset of patients participating in mo19390, and receiving avastin 15mg/kg iv on day 1 and subsequently once every 3 weeks, will undergo brcai mrna expression determination. depending on the brcai mrna level (low, medium or high) they will receive a different chemotherapy regimen in combination with avastin: a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel. avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * participating in, and meeting all inclusion/exclusion criteria of, mo19390. exclusion criteria: * not meeting the inclusion/exclusion criteria of mo19390.
9 months extension study of somvc001 study (gala) vascular conduit preservation solution

Conditions: Coronary Artery Disease

Summary: this is a 9-months extension to the following study, protocol number: 003-03: "a study to evaluate the use of somvc001 (gala) vascular conduit preservation solution in patients undergoing coronary artery bypass grafting (gabg)". participation is allowed exclusively to participants enrolled in the main protocol somvc001 (gala).

patients enrolled in this 9-months extension study of somvc001 (gala) will be contacted by phone twice: 6 months and 9 months after a coronary artery bypass graft (cabg) surgery. during these phone call visits and at twelve months post cabg surgery, adverse events and/or concomitant medication changes will be collected from the participant. twelve months after the cabg surgery procedure, imaging will be performed using 64-slice or better mdct-scan angiography. the study participation ends at this mdct-scan visit. in detail, will be recorded incidence of composite safety outcomes consisting of major adverse cardiac events (mace) (death, myocardial infarction \[mi\], and repeat revascularization), angina, arrhythmias, shortness of breath \[sob\], decreased lumen change, graft occlusion and significant stenosis based on fitzgibbon's scale b and o, following cabg surgery. patients in this study are their own control; they receive two svg; one exposed to gala and the other exposed to heparinized dose saline. the effect of treatment (gala vs. saline) will be evaluated on paired grafts within-person. therefore, treatment effect will be presented by graft and not by patient. only adverse clinical events will be presented by patient including their potential relationship to the study product.

Eligibility criteria:
inclusion criteria: * patients from protocol #003-03 who agree to be followed for an additional 9 months by signing informed consent. exclusion criteria: * patients who have a contraindication to undergo mdct angiography ant 12 months post cabg surgery.